About PTGX Dividend Returns
Protagonist Therapeutics, Inc. (PTGX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.
How We Calculate Total Return
Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.
Frequently Asked Questions
Q1What is the total return of PTGX over the past year?
Protagonist Therapeutics, Inc. (PTGX) delivered a return of 144.96% over the past year. Since PTGX does not currently pay dividends, the total return equals the price-only return.
Q2How much would $10,000 invested in PTGX be worth today?
A $10,000 investment in Protagonist Therapeutics, Inc. one year ago would be worth $24,496 today, representing a gain of $14,496.
Q3Does PTGX pay dividends?
Protagonist Therapeutics, Inc. (PTGX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For PTGX, the total return equals the price-only return.
Q4Did PTGX beat the S&P 500?
Yes, Protagonist Therapeutics, Inc. (PTGX) outperformed the S&P 500 by 129.51 percentage points over the past year. PTGX delivered a total return of 144.96%, compared to the S&P 500's 15.45%. This 129.51pp alpha means investors in PTGX earned more than a passive S&P 500 index fund.
Q5What is PTGX's worst drawdown?
Protagonist Therapeutics, Inc. (PTGX) experienced a maximum drawdown of -31.58% over the past year, declining from its peak on 2025-03-11 to its trough on 2025-04-10. The stock recovered to its prior peak by 2025-08-27. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.
Q6What is PTGX's long-term total return over 10, 20, or 30 years?
Protagonist Therapeutics, Inc. (PTGX) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is 687.0% (22.9% CAGR) — $10,000 would have grown to $78,701. Over 20 years: 687.0% total return (10.9% CAGR) — $10,000 → $78,702. Over 30 years: 687.0% total return (7.1% CAGR) — $10,000 → $78,702. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.
Q7What was PTGX's best and worst year?
Protagonist Therapeutics, Inc.'s best calendar year was 2020 with a total return of 190.9%. Its worst year was 2022 with a total return of -69.1%. This range shows the volatility investors should expect — the difference between the best and worst year is 260.0 percentage points.
Find the Best Dividend Stocks
Screen for dividend stocks with the highest total returns (including DRIP).